365mc and Raziel Therapeutics Announce Strategic Collaboration to Accelerate Development of RZL-012 in South Korea

SEOUL, South Korea and TEL AVIV, Israel, July 15, 2025 /PRNewswire/ -- 365mc, South Korea's leading medical institution specializing in fat reduction treatments, and Raziel Therapeutics, a global clinical-stage biopharmaceutical company, have announced a strategic collaboration to jointly advance the clinical and commercial development of RZL-012 in South Korea. RZL-012 is an innovative injectable treatment for focal fat reduction that is currently progressing toward Phase 3 trials.

365mc is renowned for its patient-centered and comprehensive approach to fat management, offering an integrated continuum of services encompassing surgical procedures, dietary counseling, and behavioral therapy. As South Korea's No.1 and foremost medical network specializing in fat management and reduction, 365mc operates 21 branches nationwide. Leveraging its domestic leadership, the organization is rapidly expanding its global presence, with successful market entries in Indonesia, Thailand, and Vietnam, and a recent expansion confirmed in the United States—firmly positioning 365mc as a leading international authority in body contouring.

Raziel Therapeutics is developing RZL-012, a New Chemical Entity (NCE) designed to selectively disrupt adipocyte membranes, leading to a reduction in localized subcutaneous fat. The drug is intended for aesthetic applications, including the treatment of submental fat ("double chin") and non-surgical body contouring. Clinical trials have shown that RZL-012 induces adipocyte cell death, resulting in a significant and lasting reduction in fat volume at the injection site.

Through this collaboration, the two companies will jointly design and implement the Phase 3 clinical strategy for RZL-012 in South Korea. Leveraging its extensive clinical experience, regulatory expertise, brand-building capabilities, and market access, 365mc will play a critical role in positioning RZL-012 as a best-in-class solution in the Korean aesthetic medicine market.

In addition, the companies will explore the development of a next-generation body contouring protocol by combining RZL-012 with 365mc's proprietary LAMS (Liposuction Assisted Modeling System) procedure. LAMS is an innovative surgical technique for focal fat reduction developed by 365mc and is expected to serve as a platform for global market expansion through an integrated treatment solution.

As part of this partnership, 365mc will also make a strategic investment in Raziel Therapeutics, further underscoring its commitment to advancing innovation in the field of non-surgical fat reduction.

This agreement was initiated and facilitated by Yozma Group, a Nasdaq-focused strategic investment firm that has been supporting Raziel Therapeutics' global expansion. Moving forward, Yozma Group will continue to play a key role in supporting the global business development and international growth of both companies.

This partnership represents a convergence of 365mc's leadership in obesity and aesthetic medicine with Raziel Therapeutics' cutting-edge fat reduction technology. Together, the companies are poised to set a new global standard in non-invasive body contouring, not only in South Korea but across international markets.

Contact:
Alon Bloomenfeld
[email protected]
+972542325070

Photo - https://mma.prnewswire.com/media/2730474/Raziel_Therapeutics_MOU_Signing.jpg

SOURCE Raziel Therapeutics